Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • SCIB1: Completed Phase I/II enrollment

    Scancell Holdings plc (LSE:SCLP; Xetra:SCP), Nottingham, U.K. Product: SCIB1 Business: Cancer Molecular target: Tyrosinase-related protein 2 (TRP-2) (TYRP2) (DCT) Description: Cancer vaccine comprising the melanoma …

    Published on 7/27/2015
  • THR-184: Completed Phase II enrollment

    Thrasos Therapeutics Inc., Montreal, Quebec Product: THR-184 Business: Renal Molecular target: Activin receptor-like kinase 2 (ALK2) (ACVR1); Activin receptor-like kinase 3 (ALK3) Description: Small peptide that …

    Published on 7/27/2015
  • Vigil vaccine: Phase IIb start

    Gradalis Inc., Dallas, Texas Product: Vigil vaccine (formerly FANG vaccine) Business: Cancer Molecular target: Transforming growth factor (TGF) beta 1 (TGFB1); Transforming growth factor (TGF) beta 2 (TGFB2) Description…

    Published on 7/27/2015
  • VRS-317: Phase III ongoing

    Amunix Operating Inc., Mountain View, Calif. Versartis Inc. (NASDAQ:VSAR), Redwood City, Calif. Product: VRS-317 Business: Endocrine/Metabolic Molecular target: NA Description: Long-acting recombinant human growth …

    Published on 7/27/2015
  • Zoptarelin doxorubicin acetate: Completed Phase III enrollment

    Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS), Quebec City, Quebec Ergomed plc (LSE:ERGO), Guilford, U.K. Product: Zoptarelin doxorubicin acetate (AEZS-108) (formerly ZEN-008, AN-152) Business: Cancer Molecular target: …

    Published on 7/27/2015
  • AG-881: Phase I started

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Product: AG-881 Business: Cancer Molecular target: Isocitrate dehydrogenase 1 (IDH1); Isocitrate dehydrogenase 2 (IDH2…

    Published on 7/20/2015
  • Amantadine: Completed Phase III enrollment

    Adamas Pharmaceuticals Inc. (NASDAQ:ADMS), Emeryville, Calif. Product: Amantadine (ADS-5102) Business: Neurology Molecular target: NA Description: Oral extended-release formulation of amantadine Indication: Treat …

    Published on 7/20/2015
  • APL-130277: Phase III started

    Cynapsus Therapeutics Inc. (TSX:CTH; NASDAQ:CYNA), Toronto, Ontario Product: APL-130277 Business: Neurology Molecular target: Dopamine receptor Description: Sublingual thin film strip formulation of apomorphine, a small…

    Published on 7/20/2015
  • Bertilimumab: Phase II started

    iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF), Vancouver, B.C. Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP), New York, N.Y. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Bertilimumab (iCo-008, CAT-…

    Published on 7/20/2015
  • BLZ-100: Phase I started

    Blaze Bioscience Inc., Seattle, Wash. Product: BLZ-100 (formerly CyTP 007) Business: Diagnostic Molecular target: NA Description: Variant of the peptide chlorotoxin, derived from scorpion venom, combined with a near-…

    Published on 7/20/2015
  • CPX-351: Phase II started

    Celator Pharmaceuticals Inc. (NASDAQ:CPXX), Ewing, N.J. Product: CPX-351 Business: Cancer Molecular target: DNA polymerase; Topoisomerase II (TOP2) Description: Liposomal formulation of cytarabine and daunorubicin …

    Published on 7/20/2015
  • Custirsen sodium: Phase III amended

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI), Bothell, Wash. Product: Custirsen sodium (TV-1011, OGX-011) Business: Cancer Molecular target: Clusterin mRNA …

    Published on 7/20/2015
  • Custirsen sodium: Phase III ongoing

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI), Bothell, Wash. Product: Custirsen sodium (TV-1011, OGX-011) Business: Cancer Molecular target: Clusterin mRNA …

    Published on 7/20/2015
  • EGP-437: Phase Ib/IIa started

    EyeGate Pharmaceuticals Inc. (OTCQB:EYEG), Waltham, Mass. Product: EGP-437 Business: Ophthalmic Molecular target: NA Description: Dexamethasone phosphate ophthalmic solution delivered by the EyeGate II Drug Delivery …

    Published on 7/20/2015
  • ETC-159: Phase I started

    Agency for Science, Technology and Research, Singapore Product: ETC-159 Business: Cancer Molecular target: NA Description: Inhibitor of the Wnt cell signaling pathway Indication: Treat advanced solid tumors Endpoint: …

    Published on 7/20/2015
  • FR104: Phase I started

    Effimune S.A.S., Nantes, France Product: FR104 Business: Autoimmune Molecular target: CD28 receptor Description: Pegylated monovalent antibody fragment antagonist of CD28 receptor Indication: Treat immune-mediated …

    Published on 7/20/2015
  • Galeterone: Phase III started

    Tokai Pharmaceuticals Inc. (NASDAQ:TKAI), Cambridge, Mass. Product: Galeterone (TOK-001) Business: Cancer Molecular target: Androgen receptor; Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) (CYP17A) …

    Published on 7/20/2015
  • Horizant gabapentin enacarbil: Phase II started

    XenoPort Inc. (NASDAQ:XNPT), Santa Clara, Calif. Product: Horizant gabapentin enacarbil (Regnite) (GSK1838262, XP13512) Business: Neurology Molecular target: Calcium channel N-type Description: Transported prodrug of …

    Published on 7/20/2015
  • HP-3150: Phase II/III started

    Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530), Tosu, Japan Product: HP-3150 Business: Neurology Molecular target: NA Description: Transdermal patch containing NSAIDs Indication: Treat cancer pain Endpoint: NA Status: …

    Published on 7/20/2015
  • IV solithromycin: Completed Phase III enrollment

    Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C. Toyama Chemical Co. Ltd., Tokyo, Japan Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: IV solithromycin (CEM-101) (formerly OPT-1068) Business: Infectious Molecular …

    Published on 7/20/2015
  • Lagova: Completed Phase III enrollment

    Opko Health Inc. (NYSE:OPK; Tel Aviv:OPK), Miami, Fla. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Lagova, hGH-CTP (PF-06836922, MOD-4023) Business: Endocrine/Metabolic Molecular target: NA Description: Long-acting …

    Published on 7/20/2015
  • NBTXR3: Phase I/II start

    Nanobiotix S.A. (Euronext:NANO), Paris, France PharmaEngine Inc. (GreTai:4162), Taipei, Taiwan Product: NBTXR3, PEP503 Business: Cancer Molecular target: DNA Description: Crystalline nanoparticles of hafnium oxide …

    Published on 7/20/2015
  • Omadacycline: Phase III started

    Paratek Pharmaceuticals Inc. (NASDAQ:PRTK), Boston, Mass. Product: Omadacycline (formerly PTK 0796) Business: Infectious Molecular target: Ribosomal 30S subunit Description: Aminomethylcycline antibiotic Indication: …

    Published on 7/20/2015
  • Oral BAL101553: Phase I/IIa started

    Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland Product: Oral BAL101553 Business: Cancer Molecular target: Tubulin Description: Water-soluble prodrug of BAL27862, an apoptosis-inducing small molecule targeting …

    Published on 7/20/2015
  • oral RTA 408: Phase II started

    Reata Pharmaceuticals Inc., Irving, Texas Product: oral RTA 408 Business: Endocrine/Metabolic Molecular target: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2); Nuclear factor of kappa light polypeptide gene…

    Published on 7/20/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993